Tiotropium Bromide: an Update
Overview
Authors
Affiliations
Tiotropium bromide is a once-daily inhaled anticholinergic bronchodilator. It works by blocking the muscarinic receptors in airway smooth muscle. Tiotropium has a wide therapeutic margin, due to its poor gastrointestinal absorption and its very low systemic bioavailability. The drug is mainly indicated in COPD patients. Clinically relevant outcomes such as significant improvements in spirometry, hyperinflation, dyspnea, heath status, acute exacerbations and mortality have been consistently observed in tiotropium clinical trials, and the drug has been shown to reduce the risk of mortality due to cardiac-vascular disease and respiratory failure. The main side effect reported is dryness of the mouth. Some subgroups of asthmatics also seem to respond to anticholinergic drugs: among them, those with the Arg/Arg genotype for the beta2-adrenergic receptor and those with a high percentage of neutrophils in sputum.
Future perspectives of anticholinergics for the treatment of asthma in adults and children.
Buhl R, Hamelmann E Ther Clin Risk Manag. 2019; 15:473-485.
PMID: 30936709 PMC: 6422409. DOI: 10.2147/TCRM.S180890.
Ogasawara T, Sakata J, Aoshima Y, Tanaka K, Yano T, Kasamatsu N Intern Med. 2017; 56(18):2401-2406.
PMID: 28824055 PMC: 5643165. DOI: 10.2169/internalmedicine.8255-16.
Hyun M, Lee N, Jang E, Yim J, Lee C Int J Chron Obstruct Pulmon Dis. 2016; 11:747-54.
PMID: 27114705 PMC: 4833365. DOI: 10.2147/COPD.S96969.